Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 5, 2012, Pages 1572-1580

  Lee, Peter A ^a,b   Klein, Karen ^c   Mauras, Nelly ^d   Neely, Kirk E ^e   Bloch, Clifford A ^f,g   Larsen, Lois ^h   Mattia Goldberg, Cynthia ^h   Chwalisz, Kristof ^h  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NEMOURS CHILDREN S CLINIC   (United States)

^e STANFORD UNIVERSITY   (United States)

^f Pediatric Endocrine Associates   (United States)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^h ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; FOLLITROPIN; LEUPRORELIN; LUTEINIZING HORMONE; TESTOSTERONE;

ARTICLE; BONE AGE; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; FEVER; GROWTH RATE; HEADACHE; HORMONE DETERMINATION; HUMAN; INJECTION SITE PAIN; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MULTICENTER STUDY; NOSE CONGESTION; ONSET AGE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRECOCIOUS PUBERTY; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHOOL CHILD; SIDE EFFECT; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN;

CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; INFANT; LEUPROLIDE; LUTEINIZING HORMONE; MALE; PUBERTY, PRECOCIOUS; TESTOSTERONE; TREATMENT OUTCOME;

EID: 84860744203     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-2704     Document Type: Article

References (29)

1. Carel JC, Eugster EA, Rogo LA, Ghizzoni L, Palmert MR, Antoniazzi F, Berenbaum S, Bourguignon JP, Chrousos GP, Coste J, Deal S, de Vries L, Foster C, Heger S, Holland J, Jahnukainen K, Juul A, Kaplowit ZP, Lahlo UN, Lee MM, Le EP, Merke DP, Neely EK, Oostdijk W, Phillip M, Rosenfield RL, Shulman D, Styne D, Tauber M, Wit JM 2009 Consensus statement on the use of gonadotropin- releasing hormone analogs in children. Pediatrics 123:e752-e762
2. Lee PA 1999 Central precocious puberty. An overview of diagnosis, treatment, and outcome. Endocrinol Metab Clin North Am 28:901-918, xi
3. Mul D, Hughes IA 2008 The use of GnRH agonists in precocious puberty. Eur J Endocrinol 159(Suppl 1):S3-S8
4. Parker KL, Lee PA 1989 Depot leuprolide acetate for treatment of precocious puberty. J Clin Endocrinol Metab 69:689-691
5. Product insert 2011 Lupron Depot-PED. NorthChica go, IL: Abbott Laboratories
6. Lee P 1993 Treatment of central precocious puberty with depot Lupron. In: Grave G, Cutler Jr GB, eds. Sexual precocity: etiology, diagnosis, and management. New York: Raven Press; 139-150
7. Parker K, Lee PA 1995 Treatment of girls with central precocious puberty with depot GnRH analogue therapy. In: Plant T, Lee PA, eds. The neurobiology of puberty. Bristol, UK: J Endocrinology Ltd; 297-302
8. Lee PA, Neely EK, Fuqua J, Yang D, Larsen LM, Mattia-Goldberg C, Chwalisz K 2011 Efficacy ofleuprolide acetate 1-month depot for central precocious puberty (CPP): growth outcomes during a prospective, longitudinal study. Int J Pediatr Endocrinol 2011:7
9. Neely EK, Lee PA, Bloch CA, Larsen L, Yang D, Mattia-Goldberg C, Chwalisz K 2010 Leuprolide acetate 1-month depot for central precocious puberty: hormonal suppression and recovery. Int J Pediatr Endocrinol 2010:398639
10. Mericq V, Lammoglia JJ, Unanue N, Villaroel C, Hernández MI, Avila A, Iñiguez G, Klein KO 2009 Comparison of three doses of leuprolide acetate in the treatment of central precocious puberty: preliminary results. Clin Endocrinol (Oxf) 71:686-690
11. Badaru A, Wilson DM, Bachrach LK, Fechner P, Gandrud LM, Durham E, Wintergerst K, Chi C, Klein KO, Neely EK 2006 Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty. J Clin Endocrinol Metab 91:1862-1867
12. Carel JC, Lahlou N, Jaramillo O, Montauban V, Teinturier C, Colle M, Lucas C, Chaussain JL 2002 Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg). J Clin Endocrinol Metab 87:4111-4116
13. Product insert 2008 Lupron Depot 3-Month 11.25 mg. North Chicago, IL: Abbott Laboratories
14. Product insert 2008 Lupron Depot 4-month 30mg. North Chicago, IL: Abbott Laboratories
15. Roche A, Chumlea WC, Thissen D 1988 Assessing the skeletal maturity of the hand wrist: FELS method. Springfield, IL: Charles C. Thomas
16. Bonat S, Pathomvanich A, Keil MF, Field AE, Yanovski JA 2002 Self-assessment of pubertal stage in overweight children. Pediatrics 110:743-747
17. Brown R 2002 Adolescent growth and development. In: Holland-Hall C, Brown RT, eds. Adolescent medicine secrets. Philadelphia: Hanley, Belfus Inc.; 21-28
18. Travers S, Slover RH 2005 Disorders of puberty. In: McDermott MT, ed. Endocrine secrets. 4th ed. Philadelphia: Elsevier Mosby; 354-367
19. Koch GG, McCanles SI, Ward Jr JF 1984 Interpretation ofstatistical methodology associated with maintenance trials. Am J Med 77:43-50
20. Parker KL, Baens-Bailon RG, Lee PA 1991 Depot leuprolide acetate dosage for sexual precocity. J Clin Endocrinol Metab 73:50-52
21. Isaac H, Patel L, Meye RS, Hall CM, Cusick C, Price DA, Clayton PE 2007 Efficacy of a monthly compared to 3-monthly depot GnRH analogue (goserelin) in the treatment of children with central precocious puberty. Horm Res 68:157-163
22. Martínez-Aguayo A, Hernández MI, Beas F, Iñiguez G, Avila A, Sovin OH, Brav OE, Cassorla F 2006 Treatment of central precocious puberty with triptorelin 11.25 mg depot formulation. J Pediatr Endocrinol Metab 19:963-970
23. Trueman JA, Tillmann V, Cusick CF, Foster P, Patel L, Hall CM, Price DA, Clayton PE 2002 Suppression of puberty with long-acting goserelin (Zoladex-LA): effect on gonadotrophin response to GnRH in the first treatment cycle. Clin Endocrinol (Oxf) 57:223-230
24. Carel JC, Blumberg J, Seymour C, Adamsbaum C, Lahlou N 2006 Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty. Eur J Endocrinol 154:119-124
25. Carel JC, Léger J 2008 Clinical practice. Precocious puberty. N Engl J Med 358:2366-2377
26. Houk CP, Kunselman AR, Lee PA 2009 Adequacy of a single unstimulated luteinizing hormone level to diagnose central precocious puberty in girls. Pediatrics 123:e1059-e1063
27. Neely EK, Wilson DM, Lee PA, Stene M, Hintz RL 1995 Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty. J Pediatr 127:47-52
28. Carel JC, Lahlou N, Roger M, Chaussain JL 2004 Precocious puberty and statural growth. Hum Reprod Update 10:135-147
29. Mostafa N, Chwalisz K, Larsen L, Mattia-Goldberg C, Young JM, Spit ZA, Pradhan R 2010 Pharmacokinetics and pharmacodynamics of leuprolide acetate 6-month depotinpatients with prostate cancer. J Clin Pharmacol 50:1058-1095